484 related articles for article (PubMed ID: 22458564)
41. Immunologic Mediators in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Saeed HN; Chodosh J
Semin Ophthalmol; 2016; 31(1-2):85-90. PubMed ID: 26959133
[TBL] [Abstract][Full Text] [Related]
42. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Cristallo AF; Schroeder J; Citterio A; Santori G; Ferrioli GM; Rossi U; Bertani G; Cassano S; Gottardi P; Ceschini N; Barocci F; Ribizzi G; Cutrupi V; Cairoli R; Rapisarda V; Pastorello EA; Barocci S
Int J Immunogenet; 2011 Aug; 38(4):303-9. PubMed ID: 21545408
[TBL] [Abstract][Full Text] [Related]
43. Nonpigmenting fixed drug eruption as a possible abortive variant of toxic epidermal necrolysis: immunohistochemical and serum cytokine analyses.
Mizukawa Y; Shiohara T
Clin Exp Dermatol; 2010 Jul; 35(5):493-7. PubMed ID: 19874369
[TBL] [Abstract][Full Text] [Related]
44. T cell populations propagating in the peripheral blood of patients with drug eruptions.
Nishio D; Izu K; Kabashima K; Tokura Y
J Dermatol Sci; 2007 Oct; 48(1):25-33. PubMed ID: 17601705
[TBL] [Abstract][Full Text] [Related]
45. Anti-desmoplakin antibodies in erythema multiforme and Stevens-Johnson syndrome sera: pathogenic or epiphenomenon?
Cozzani E; Di Zenzo G; Calabresi V; Caproni M; Schena D; Quaglino P; Marzano AV; Fabbri P; Rebora A; Parodi A
Eur J Dermatol; 2011; 21(1):32-6. PubMed ID: 21233064
[TBL] [Abstract][Full Text] [Related]
46. Toll-like receptor 9 polymorphism in patients with erythema multiforme, Stevens Johnson syndrome and Stevens Johnson syndrome/toxic epidermal necrolysis overlap syndrome.
Turan H; Bulbul Baskan E; Yakut T; Karkucak M; Tunali S; Saricaoglu H
Bratisl Lek Listy; 2011; 112(5):260-3. PubMed ID: 21682079
[TBL] [Abstract][Full Text] [Related]
47. Mucosal disease series. Number IV. Erythema multiforme.
Farthing P; Bagan JV; Scully C
Oral Dis; 2005 Sep; 11(5):261-7. PubMed ID: 16120111
[TBL] [Abstract][Full Text] [Related]
48. HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4⁺ T cells.
Yang C; Mosam A; Mankahla A; Dlova N; Saavedra A
J Am Acad Dermatol; 2014 Jun; 70(6):1096-102. PubMed ID: 24629995
[TBL] [Abstract][Full Text] [Related]
49. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.
Schwartz RA; McDonough PH; Lee BW
J Am Acad Dermatol; 2013 Aug; 69(2):187.e1-16; quiz 203-4. PubMed ID: 23866879
[TBL] [Abstract][Full Text] [Related]
50. Serum interleukin-13 levels are increased in patients with Stevens-Johnson syndrome/ toxic epidermal necrolysis but not in those with erythema multiforme.
Quaglino P; Caproni M; Osella-Abate S; Torchia D; Comessatti A; Del Bianco E; Antiga E; Frezzolini A; Schena D; Marzano A; De Simone C; Parodi A; Fabbri P; Bernengo MG
Br J Dermatol; 2008 Jan; 158(1):184-6. PubMed ID: 17941938
[No Abstract] [Full Text] [Related]
51. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Morel E; Escamochero S; Cabañas R; Díaz R; Fiandor A; Bellón T
J Allergy Clin Immunol; 2010 Mar; 125(3):703-10, 710.e1-710.e8. PubMed ID: 20132973
[TBL] [Abstract][Full Text] [Related]
52. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
Yang Y; Xu J; Li F; Zhu X
Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
[TBL] [Abstract][Full Text] [Related]
53. Possible involvement of gelatinase A (MMP2) and gelatinase B (MMP9) in toxic epidermal necrolysis or Stevens-Johnson syndrome.
Gaultier F; Ejeil AL; Igondjo-Tchen S; Dohan D; Dridi SM; Maman L; Wierzba CB; Stania D; Pellat B; Lafont A; Godeau G; Gogly B
Arch Dermatol Res; 2004 Oct; 296(5):220-5. PubMed ID: 15449075
[TBL] [Abstract][Full Text] [Related]
54. Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Fujita Y; Yoshioka N; Abe R; Murata J; Hoshina D; Mae H; Shimizu H
J Am Acad Dermatol; 2011 Jul; 65(1):65-8. PubMed ID: 21507517
[TBL] [Abstract][Full Text] [Related]
55. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Lipowicz S; Sekula P; Ingen-Housz-Oro S; Liss Y; Sassolas B; Dunant A; Roujeau JC; Mockenhaupt M
Br J Dermatol; 2013 Apr; 168(4):726-32. PubMed ID: 23413807
[TBL] [Abstract][Full Text] [Related]
56. Epidermal necrolysis: 60 years of errors and advances.
Heng YK; Lee HY; Roujeau JC
Br J Dermatol; 2015 Nov; 173(5):1250-4. PubMed ID: 26769645
[TBL] [Abstract][Full Text] [Related]
57. Erythema multiforme: a review and contrast from Stevens-Johnson syndrome/toxic epidermal necrolysis.
Williams PM; Conklin RJ
Dent Clin North Am; 2005 Jan; 49(1):67-76, viii. PubMed ID: 15567361
[TBL] [Abstract][Full Text] [Related]
58. [Severe skin reactions. Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema exsudativum multiforme majus and generalized bullous fixed drug exanthema].
Rzany B; Mockenhaupt M; Baur S; Stocker U; Schöpf E
Hautarzt; 1993 Aug; 44(8):549-54; quiz 554-6. PubMed ID: 8376113
[No Abstract] [Full Text] [Related]
59. Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis.
Noe MH; Micheletti RG
Clin Dermatol; 2020; 38(6):607-612. PubMed ID: 33341195
[TBL] [Abstract][Full Text] [Related]
60. Clinical characteristics of childhood erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Taiwanese children.
Lam NS; Yang YH; Wang LC; Lin YT; Chiang BL
J Microbiol Immunol Infect; 2004 Dec; 37(6):366-70. PubMed ID: 15599469
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
